Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies
Sponsor: Novartis Pharmaceuticals
Summary
KAIROS was a prospective, multicenter, non-interventional study (NIS) in Germany. Prospective, primary data was collected via questionnaires and an electronic case report form (eCRF) over a period of one year (max. 1.5 years) of treatment. Additionally, medical history of participants was collected including disease duration, EDSS, MRI parameters and relapses.
Official title: A Non-interventional Study Evaluating Kesimpta® (Ofatumumab) Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies [KAIROS]
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
307
Start Date
2022-10-28
Completion Date
2025-05-28
Last Updated
2026-05-29
Healthy Volunteers
No
Conditions
Interventions
Ofatumumab
There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
Locations (40)
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Bamberg, Bavaria, Germany
Novartis Investigative Site
Bad Homburg, Hesse, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Marburg, Hesse, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Altenburg, Thuringia, Germany
Novartis Investigative Site
Alzey, Germany
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bogen, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Böblingen, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Gelsenkirchen, Germany
Novartis Investigative Site
Giessen, Germany
Novartis Investigative Site
Gladenbach, Germany
Novartis Investigative Site
Hagen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Kaiserslautern, Germany
Novartis Investigative Site
Minden, Germany
Novartis Investigative Site
Osnabrück, Germany
Novartis Investigative Site
Pforzheim, Germany
Novartis Investigative Site
Quakenbrück, Germany
Novartis Investigative Site
Remscheid, Germany
Novartis Investigative Site
Rülzheim, Germany
Novartis Investigative Site
Siegen, Germany
Novartis Investigative Site
Sinsheim, Germany
Novartis Investigative Site
Stuttgart, Germany
Novartis Investigative Site
Stuttgart, Germany
Novartis Investigative Site
Unterhaching, Germany